as the article probably said..this is adding deuterium to an old drug that has been around for a while. The pharma for the old stuff is Lundborg, supposedly o

as the article probably said..this is adding deuterium to an old drug that has been around for a while. The pharma for the old stuff is Lundborg, supposedly one of the "non-profit" pharmas focused on orphan drugs. Pricing is high, mostly due to supply constraints, so they say, but the foundation attached to the company gives patients some sort of financial advice. Basically, the drug induces a form of parkinsonism (hypokineticism) to combat conditions that cause hyperkineticism.